Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial.

Langley RG, Paller AS, Hebert AA, Creamer K, Weng HH, Jahreis A, Globe D, Patel V, Orlow SJ.

J Am Acad Dermatol. 2011 Jan;64(1):64-70. doi: 10.1016/j.jaad.2010.02.060. Epub 2010 Jul 8.

PMID:
20619489
2.

Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.

Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, Jahreis A.

Br J Dermatol. 2005 Dec;153(6):1192-9.

PMID:
16307657
3.

Etanercept for psoriasis in the pediatric population: experience in nine patients.

Hawrot AC, Metry DW, Theos AJ, Levy ML.

Pediatr Dermatol. 2006 Jan-Feb;23(1):67-71.

PMID:
16445417
4.

Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial.

Prinz JC, Fitzgerald O, Boggs RI, Foehl J, Robertson D, Pedersen R, Molta CT, Freundlich B.

J Eur Acad Dermatol Venereol. 2011 May;25(5):559-64. doi: 10.1111/j.1468-3083.2010.03838.x. Epub 2010 Sep 14.

PMID:
20840349
5.

Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.

Reich K, Segaert S, Van de Kerkhof P, Durian C, Boussuge MP, Paolozzi L, Wajdula J, Boggs R.

Dermatology. 2009;219(3):239-49. doi: 10.1159/000237871. Epub 2009 Sep 10.

PMID:
19752505
6.

A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.

Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, Stevens SR.

J Am Acad Dermatol. 2007 Apr;56(4):598-603. Epub 2006 Nov 17.

PMID:
17113190
7.

Validation and response to treatment of a pruritus self-assessment tool in patients with moderate to severe psoriasis.

Gottlieb A, Feng J, Harrison DJ, Globe D.

J Am Acad Dermatol. 2010 Oct;63(4):580-6. doi: 10.1016/j.jaad.2009.09.049.

PMID:
20599294
8.

Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis.

Landells I, Paller AS, Pariser D, Kricorian G, Foehl J, Molta C, Freundlich B.

Eur J Dermatol. 2010 May-Jun;20(3):323-8. doi: 10.1684/ejd.2010.0911. Epub 2010 Feb 25.

PMID:
20185386
9.

Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from a randomized, double-blind, placebo-controlled study of etanercept.

Tyring S, Bagel J, Lynde C, Klekotka P, Thompson EH, Gandra SR, Shi Y, Kricorian G.

J Eur Acad Dermatol Venereol. 2013 Jan;27(1):125-8. doi: 10.1111/j.1468-3083.2011.04394.x. Epub 2011 Dec 21. No abstract available.

PMID:
22188302
10.

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.

Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A.

Arch Dermatol. 2007 Jun;143(6):719-26.

PMID:
17576937
11.

Initial experience with routine administration of etanercept in psoriasis.

de Groot M, Appelman M, Spuls PI, de Rie MA, Bos JD.

Br J Dermatol. 2006 Oct;155(4):808-14.

PMID:
16965432
12.

Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial.

Feldman SR, Kimball AB, Krueger GG, Woolley JM, Lalla D, Jahreis A.

J Am Acad Dermatol. 2005 Nov;53(5):887-9.

PMID:
16243150
13.

Etanercept treatment for children and adolescents with plaque psoriasis.

Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, Hebert AA, Eichenfield LF, Patel V, Creamer K, Jahreis A; Etanercept Pediatric Psoriasis Study Group.

N Engl J Med. 2008 Jan 17;358(3):241-51. doi: 10.1056/NEJMoa066886.

14.

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.

Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L; Etanercept Psoriasis Study Group.

Br J Dermatol. 2005 Jun;152(6):1304-12.

PMID:
15948997
15.

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.

Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE.

Br J Dermatol. 2006 Jun;154(6):1161-8.

PMID:
16704649
16.

Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus.

Martínez-Abundis E, Reynoso-von Drateln C, Hernández-Salazar E, González-Ortiz M.

Arch Dermatol Res. 2007 Nov;299(9):461-5. Epub 2007 Aug 28.

PMID:
17726611
17.

Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.

Driessen RJ, Boezeman JB, van de Kerkhof PC, de Jong EM.

Br J Dermatol. 2009 Mar;160(3):670-5. doi: 10.1111/j.1365-2133.2008.09019.x. Epub 2008 Jan 28.

PMID:
19210502
18.

Treatment of severe nail psoriasis with etanercept.

Coelho JD, Diamantino F, Lestre S, Ferreira AM.

Indian J Dermatol Venereol Leprol. 2011 Jan-Feb;77(1):72-4. doi: 10.4103/0378-6323.74996. No abstract available.

19.

Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.

Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, Chang T.

J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S101-11.

PMID:
16488320
20.

Long-term etanercept in pediatric patients with plaque psoriasis.

Paller AS, Siegfried EC, Eichenfield LF, Pariser D, Langley RG, Creamer K, Kricorian G.

J Am Acad Dermatol. 2010 Nov;63(5):762-8. doi: 10.1016/j.jaad.2010.04.004. Epub 2010 Jun 3.

PMID:
20605256

Supplemental Content

Support Center